AgaMatrix raises $56M to develop and sell its WaveForm CGM

Cash register full of money
WaveForm also inked a distribution deal with A. Menarini Diagnostics, based in Florence, Italy, to bring its CGM offering to Europe, the Middle East, Africa and Latin America. (Michael Burrell / iStock / Getty Images Plus)

The diabetes diagnostic-focused AgaMatrix has secured a capital raise of about $56 million, with plans to support clinical trials of a continuous glucose monitoring system being developed under its WaveForm Technologies subsidiary.

The money includes $50 million in senior financing from Perceptive Advisors, plus over $6 million from new and previous backers of the company. AgaMatrix also plans to use the proceeds to repay debt and increase production capacity, alongside the CGM’s commercialization in Europe and preparations ahead of an FDA clearance.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"There is great opportunity for our innovative sensor technology to capture significant market share through increased investment in production equipment, research and development and operational resources afforded by the latest financing," AgaMatrix CFO Jackson McAdam said in a statement.

"We are also excited by the favorable results of the WaveForm continuous glucose monitor in clinical trials, and eager to pursue the significant market opportunity for our WaveForm product across both Type 1 and Type 2 diabetes segments,” McAdam added.

WaveForm recently inked a distribution deal with A. Menarini Diagnostics, based in Florence, Italy, to bring its CGM offering to Europe, the Middle East, Africa and Latin America.

The monitoring system will also integrate with A. Menarini’s connected diabetes care platform. Additionally, A. Menarini and AgaMatrix are discussing terms to commercialize a Bluetooth-enabled blood glucose monitor and future products, the companies said.

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Elon Musk pulled back the curtain on his brain interface-developing Neuralink, saying the startup holds the promise of merging people with AI.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.